加载中
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate). These cytokine therapies are ingeniously engineered with a protein domain that keeps them inactive until proteases specific to the tumor microenvironment (TME) cleave this mask, thereby initiating their therapeutic activity. Xilio Therapeutics, Inc. was founded in 2016 and is based in Waltham, Massachusetts.
收盘时
US$9.075
+US$0.025 · +0.28%
盘中时间采用ET。市场数据可能有所延迟。
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate). These cytokine therapies are ingeniously engineered with a protein domain that keeps them inactive until proteases specific to the tumor microenvironment (TME) cleave this mask, thereby initiating their therapeutic activity. Xilio Therapeutics, Inc. was founded in 2016 and is based in Waltham, Massachusetts.
日内区间
当前US$9.075
52周区间
当前US$9.075
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
88
深度低估
情绪
45
多空交织
风险
45
风险偏高
动量
43
中性
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate). These cytokine therapies are ingeniously engineered with a protein domain that keeps them inactive until proteases specific to the tumor microenvironment (TME) cleave this mask, thereby initiating their therapeutic activity. Xilio Therapeutics, Inc. was founded in 2016 and is based in Waltham, Massachusetts.
日内区间
当前US$9.075
52周区间
当前US$9.075
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 4376.6万 USD | 634.4万 USD | — | — | — |
| 销货成本 | 154.1万 USD | — | — | — | 149.9万 USD |
| 毛利 | 4222.5万 USD | 634.4万 USD | — | — | −149.9万 USD |
| 研究与开发 | 5603.9万 USD | 4121.1万 USD | 5213.6万 USD | 5920.1万 USD | 5118.8万 USD |
| 销售、一般及管理费用 | 2970.9万 USD | 2477.8万 USD | 2699.7万 USD | 2994.8万 USD | 2235.7万 USD |
| 营业费用 | 8420.7万 USD | 6692.6万 USD | 7913.3万 USD | 8914.9万 USD | 7354.5万 USD |
| 利息收入 | 340万 USD | — | — | — | 600 USD |
| 利息支出 | — | 10万 USD | — | — | 60万 USD |
| 折旧和摊销 | 154.1万 USD | 164.4万 USD | 190万 USD | 184.7万 USD | 149.9万 USD |
| 营业利润 | −4198.2万 USD | −6058.2万 USD | −7913.3万 USD | −8914.9万 USD | −7504.4万 USD |
| 净利润 | −3503.6万 USD | −5824.1万 USD | −7640.4万 USD | −8822.2万 USD | −7580万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$98.00
上涨空间 979.89%评级样本有限，仅3项
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年3月16日 | 1:14 | — | — |
已生效 2026年3月16日
1:14
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
